Certara, Inc.

On February 24, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to appoint Arjun Bedi as a Class III director of the Board and a member of the Audit Committee of the Board, effective immediately. In connection with the appointment of Mr. Bedi, the size of the Board was increased from ten (10) to eleven (11) directors. Mr. Bedi was appointed to serve as a member of the Board until the 2026 annual meeting of stockholders and his successor is duly elected and qualified, or until his earlier death, disqualification or removal.

Mr. Bedi will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation policy described in “Board and Governance Practices − Director Compensation” of the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2025. The Company intends to enter into an indemnification agreement with Mr. Bedi substantially similar to the indemnification agreements the Company has entered into with other members of the Board.

There are no family relationships between Mr. Bedi and any of the directors or executive officers of the Company, and there are no transactions in which Mr. Bedi has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr. Bedi and any other person pursuant to which Mr. Bedi was selected as a director of the Company.

(b) Director and Officer 10b5-1 Trading Arrangements

Our directors and officers may adopt written plans, referred to as Rule 10b5-1 plans, in which they arrange with a broker to buy or sell our common stock on a periodic basis. Under a Rule 10b5-1 plan, the broker executes trades based on parameters established by the director or officer when the plan is created, without further input from them. These plans are intended to meet the affirmative defense requirements of Rule 10b5-1(c) under the Exchange Act. For the three months ended December 31, 2025, no director or officer of the Company initiated orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.